Rocket Pharmaceuticals, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for RCKT, updated each market day.
RCKT AI Sentiment
AI predicts Rocket Pharmaceuticals, Inc. Common Stock stock is likely to increase over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Rocket Pharmaceuticals, Inc. Common Stock
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Sector
Exchange
Market Cap
$392,842,213
Cap Tier
Employees
202
Headquarters
NEW YORK, NY
Listed Since
Feb. 18, 2015
Website
RCKT Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
RCKT Volatility
Rocket Pharmaceuticals, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
